Alendronic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Alendronic Acid: From Postmenopausal Osteoporosis to HIV Infectious Disease
One-Sentence Summary
Alendronic acid (alendronate) is a bisphosphonate originally used to treat osteoporosis, including postmenopausal osteoporosis, and Paget disease of bone. The TxGNN model predicts it may be effective for HIV infectious disease, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Postmenopausal osteoporosis, osteoporosis, bone Paget disease, juvenile Paget disease (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 96.78% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, alendronic acid is a nitrogen-containing bisphosphonate, a class that inhibits bone resorption, and its efficacy in osteoporosis and Paget disease is well established.
A plausible but unverified mechanistic link is that nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase and the prenylation of small GTPases, which could affect immune cell function. Bisphosphonates are also used for HIV-associated bone loss, but that concerns bone density and is not evidence of antiviral or disease-modifying activity against HIV itself.
The high score is therefore best read as a model-derived signal, not as verified evidence. Other top-ranked predictions (feline immunodeficiency syndrome and simian immunodeficiency virus infection, both at 94.8%) appear to come from the same HIV-related signal in the knowledge graph. Several lower-ranked predictions, such as deficiency anemia, megaloblastic anemia, biotin metabolic disease and a neurodevelopmental disorder, have no apparent mechanistic connection to bone-resorption inhibition.
Safety Considerations
Knowledge-graph contraindication signals (these come from model-derived drug-disease links, not from package insert text). Main groups:
- Upper gastrointestinal / oesophageal conditions: oesophagitis, oesophageal ulcer, achalasia, oesophageal dyskinesia, gastritis, duodenitis, gastro-oesophageal reflux disease
- Mineral and bone metabolism: hypercalcaemia, vitamin D deficiency, osteomalacia, rickets, hyperphosphataemia, nephrocalcinosis
- Renal conditions: kidney disease, nephrolithiasis
- Other: osteonecrosis of the jaw, atrial fibrillation
Drug Interactions: 100 interactions were recorded in total; the data compiled for this report list 20. Most are Moderate. The main ones are:
- Calcium salts (acetate, carbonate, citrate, gluconate, lactate, phosphate, and others), iron, and magnesium and aluminium-containing antacids (aluminium hydroxide, magaldrate, magnesium carbonate/chloride/citrate), kaolin and attapulgite: Moderate, likely reduced absorption of the oral bisphosphonate
- Acetylsalicylic acid and kanamycin: Moderate
- H2 blockers (famotidine, ranitidine, cimetidine): Minor
For the predicted indications, deficiency anemia raises a potential interaction concern with iron supplements. Plummer-Vinson syndrome (dysphagia with oesophageal webs) is clinically implausible and raises a safety concern, because oral alendronate can irritate the oesophagus.
Please refer to the package insert for the full warnings and contraindications.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15268P | Buffered Binosto Effervescent Tablet 70 mg | Tablet, effervescent | Not available in the data compiled for this report |
| SIN11446P | Fosamax Tablet 70 mg | Tablet, film coated | Not available in the data compiled for this report |
| SIN13152P | Fosamax Plus 70 mg/2800 IU Tablet | Tablet | Not available in the data compiled for this report |
All three licences are valid, single-ingredient registrations and are oral forms.
Conclusion and Next Steps
Decision: Hold
Rationale: The HIV prediction rests only on a model score. No clinical trials or publications were found, so it sits at evidence level L5. The suggested mechanism is unverified, and bone benefit in HIV-associated bone loss is not evidence of an effect on HIV itself. The drug is marketed in Singapore only for bone-related use, so any HIV application would be a new use.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Mechanism of action data to test the proposed link between prenylation inhibition and immune or antiviral effects
- A systematic literature and trial search for bisphosphonates in HIV beyond bone density outcomes
- Preclinical evidence of antiviral or immunomodulatory activity, if the hypothesis is to be pursued
- Review of the interaction and oesophageal safety profile for any target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.